

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

Chenguang Shen, PhD; Zhaoqin Wang, PhD; Fang Zhao, PhD; Yang Yang, MD; Jinxiu Li, MD; Jing Yuan, MD; Fuxiang Wang, MD; Delin Li, PhD; Minghui Yang, PhD; Li Xing, MM; Jinli Wei, MM; Haixia Xiao, PhD; Yan Yang, MM; Jiuxin Qu, MD; Ling Qing, MM; Li Chen, MD; Zhixiang Xu, MM; Ling Peng, MM; Yanjie Li, MM; Haixia Zheng, MM; Feng Chen, MM; Kun Huang, MM; Yujing Jiang, MM; Dongjing Liu, MD; Zheng Zhang, MD; Yingxia Liu, MD; Lei Liu, MD

 Editorial

 Audio and Video and Supplemental content

IMPORTANCE Coronavirus disease 2019 (COVID-19) is a pandemic with no specific therapeutic agents and substantial mortality. It is critical to find new treatments.

OBJECTIVE To determine whether convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

DESIGN, SETTING, AND PARTICIPANTS Case series of 5 critically ill patients with laboratory-confirmed COVID-19 and acute respiratory distress syndrome (ARDS) who met the following criteria: severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; $\text{PAO}_2/\text{FiO}_2 < 300$; and mechanical ventilation. All 5 were treated with convalescent plasma transfusion. The study was conducted at the infectious disease department, Shenzhen Third People's Hospital in Shenzhen, China, from January 20, 2020, to March 25, 2020; final date of follow-up was March 25, 2020. Clinical outcomes were compared before and after convalescent plasma transfusion.

EXPOSURES Patients received transfusion with convalescent plasma with a SARS-CoV-2-specific antibody (IgG) binding titer greater than 1:1000 (end point dilution titer, by enzyme-linked immunosorbent assay [ELISA]) and a neutralization titer greater than 40 (end point dilution titer) that had been obtained from 5 patients who recovered from COVID-19. Convalescent plasma was administered between 10 and 22 days after admission.

MAIN OUTCOMES AND MEASURES Changes of body temperature, Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe illness), $\text{PAO}_2/\text{FiO}_2$, viral load, serum antibody titer, routine blood biochemical index, ARDS, and ventilatory and extracorporeal membrane oxygenation (ECMO) supports before and after convalescent plasma transfusion.

RESULTS All 5 patients (age range, 36-65 years; 2 women) were receiving mechanical ventilation at the time of treatment and all had received antiviral agents and methylprednisolone. Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and $\text{PAO}_2/\text{FiO}_2$ increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2-specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion.

CONCLUSIONS AND RELEVANCE In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in their clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.

Author Affiliations: Author affiliations are listed at the end of this article.

Corresponding Authors: Yingxia Liu, MD (yingxialiu@hotmail.com), Zheng Zhang, MD (zhangzheng1975@aliyun.com), and Lei Liu, MD (liulei322@aliyun.com), Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen 518112, China.

JAMA. doi:10.1001/jama.2020.4783
Published online March 27, 2020.

The epidemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating in Wuhan, China, has rapidly spread worldwide.¹ As of March 24, 2020, China had reported 81 767 cases with 3281 deaths, and the World Health Organization declared coronavirus disease 2019 (COVID-19) a pandemic. As of March 18, 2020, cases were reported in approximately 195 countries.²

No specific therapeutic agents or vaccines for COVID-19 are available.³ Several therapies, such as remdesivir and favipiravir, are under investigation,^{3,4} but the antiviral efficacy of these drugs is not yet known. The use of convalescent plasma was recommended as an empirical treatment during outbreaks of Ebola virus in 2014, and a protocol for treatment of Middle East respiratory syndrome coronavirus with convalescent plasma was established in 2015.⁵ This approach with other viral infections such as SARS-CoV, H5N1 avian influenza, and H1N1 influenza also suggested that transfusion of convalescent plasma was effective.⁶⁻¹⁰ In previous reports, most of the patients received the convalescent plasma by single transfusion.⁹⁻¹¹ In a study involving patients with pandemic influenza A(H1N1) 2009 virus infection, treatment of severe infection with convalescent plasma (n = 20 patients) was associated with reduced respiratory tract viral load, serum cytokine response, and mortality.¹⁰ In another study involving 80 patients with SARS, administration of convalescent plasma was associated with a higher rate of hospital discharge at day 22 from symptom onset compared with patients who did not receive convalescent plasma.¹² Accordingly, these findings raise the hypothesis that use of convalescent plasma transfusion could be beneficial in patients infected with SARS-CoV-2.

The purpose of this study was to describe the initial clinical experience with convalescent plasma transfusion administered to critically ill patients with COVID-19.

Methods

This study was conducted at the infectious disease department, Shenzhen Third People's Hospital, Shenzhen, China, from January 20, 2020, to March 25, 2020, and the final date of follow-up was March 25, 2020. The study was approved by the ethics committees from Shenzhen Third People's Hospital, and each patient gave written informed consent.

Patients

Patients with laboratory confirmed COVID-19, diagnosed using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) (GeneoDX Co, Ltd)¹³ were eligible to receive convalescent plasma treatment if they fulfilled the following criteria: (1) had severe pneumonia with rapid progression and continuously high viral load despite antiviral treatment; (2) $\text{PAO}_2/\text{FiO}_2$ of <300 (PAO_2 measured in mm Hg and FiO_2 measured as fraction of inspired oxygen)¹⁴; and (3) were currently or had been supported with mechanical ventilation. The serum of each recipient was obtained and enzyme-linked immunosorbent assay (ELISA) and neutralizing antibody titers were tested one day prior to the convalescent plasma transfusion. The ABO blood types of the patients were determined for

Key Points

Question Could administration of convalescent plasma transfusion be beneficial in the treatment of critically ill patients with coronavirus disease 2019 (COVID-19)?

Findings In this uncontrolled case series of 5 critically ill patients with COVID-19 and acute respiratory distress syndrome (ARDS), administration of convalescent plasma containing neutralizing antibody was followed by an improvement in clinical status.

Meaning These preliminary findings raise the possibility that convalescent plasma transfusion may be helpful in the treatment of critically ill patients with COVID-19 and ARDS, but this approach requires evaluation in randomized clinical trials.

potential compatibility with the convalescent plasma donor, and each received 2 consecutive transfusions of 200 to 250 mL of ABO-compatible convalescent plasma (400 mL of convalescent plasma in total) on the same day it was obtained from the donor. The patients received antiviral agents continuously until the SARS-CoV-2 viral loads became negative.

Disease Severity Classification

Patients with laboratory-confirmed COVID-19 infection who had any of the following were considered in critical condition: (1) respiratory failure requiring mechanical ventilation, (2) shock, identified by the use of vasopressor therapy and elevated lactate levels (>2 mmol/L) despite adequate fluid resuscitation, or (3) failure of other organs requiring admission to the intensive care unit (ICU).

Donors

The 5 donors of convalescent plasma were between the ages of 18 and 60 years. The donors had recovered from SARS-CoV-2 infection and were invited to donate their convalescent plasma after written informed consent was obtained. All donors had been previously diagnosed with laboratory-confirmed COVID-19 and subsequently tested negative for SARS-CoV-2 and other respiratory viruses, as well as for hepatitis B virus, hepatitis C virus, HIV, and syphilis at the time of blood donation. The donors had been well (asymptomatic) for at least 10 days, with a serum SARS-CoV-2-specific ELISA antibody titer higher than 1:1000 and a neutralizing antibody titer greater than 40. Following donation, 400 mL of convalescent plasma was obtained from each donor by apheresis, and the plasma was immediately transfused to the recipients on the same day it was obtained.

Clinical Information

Clinical information for the 5 patients before and after convalescent plasma transfusion was obtained from a review of the hospital computer medical system and included the following: demographic data, days of admission from symptom onset, and presenting symptoms; data about various treatments, including mechanical ventilation, antiviral therapies, and steroids; clinical data, including body temperature, $\text{PAO}_2/\text{FiO}_2$, and Sequential Organ Failure Assessment (SOFA) score (range 0-24, with higher scores indicating more severe

illness); laboratory data, including white blood cell count, lymphocyte count, chemistry panels assessing liver and kidney function, cycle threshold value (Ct), inflammatory factors C-reactive protein (CRP), procalcitonin, and IL-6, and serum antibody titer (IgG, IgM, and neutralizing antibodies); data from chest imaging studies; and information on complications, such as acute respiratory distress syndrome (ARDS), bacterial pneumonia, and multiple organ dysfunction syndrome.

Quantitative RT-PCR

The qRT-PCR for SARS-CoV-2 was assessed as described previously.¹³ Nasopharyngeal specimens collected during hospitalization were sent to the laboratory in a viral transport case. Total nucleic acid extraction from the samples was performed using the QIAamp RNA Viral Kit (Qiagen), and qRT-PCR was performed using a commercial kit specific for 2019-nCoV detection (GeneoDX Co) approved by the China Food and Drug Administration. Each RT-PCR assay provided a Ct value, which is the number of cycles required for the fluorescent signal to cross the threshold for a positive test: a higher Ct value is correlated with a lower viral load. The specimens were considered positive if the Ct value was 37.0 or lower and negative if the results were undetermined. Specimens with a Ct value higher than 37 were repeated. The specimen was considered positive if the repeated results were the same as the initial result and between 37 and 40. If the repeated Ct was undetectable, the specimen was considered negative. All procedures involving clinical specimens and SARS-CoV-2 were performed in a biosafety level 3 laboratory. The Ct values of the 5

recipients were obtained on day -1, day 1, day 3, day 7, and day 12 after the transfusion.

ELISA

Microtiter plates (Sangon Biotech) were coated overnight at 4 °C with 4 µg/mL recombinant SARS-CoV-2 RBD (receptor binding domain) proteins (50 µL per well) expressed by our laboratory through 293-T cells. The plates were washed 3 times with phosphate-buffered saline (PBS) containing 0.1% vol/vol Tween-20 (PBST) and blocked with blocking solution (PBS containing 2% wt/vol nonfat dry milk) for 2 hours at 37 °C. The plates were then washed with PBST. The serum samples were diluted to 200-fold into PBS as initial concentration, and serial 3-fold dilutions of serum was added to the wells and incubated at 37 °C for 60 minutes. After 3 washes, 100 µL of horseradish peroxidase-conjugated goat anti-human IgG (for IgG antibody titer detection) and IgM (for IgM antibody titer detection) antibodies solution (Sangon Biotech) were added to each plate, respectively, and incubated at 37 °C for 60 minutes. After 5 washes, 100 µL of tetramethylbenzidine substrate (Sangon Biotech) was added at room temperature in the dark. After 15 minutes, the reaction was stopped with a 2 M H₂SO₄ solution (sulfuric acid). The absorbance was measured at 450 nm. All samples were run in triplicate. The ELISA titers were determined by end point dilution.

Serum Neutralization Assay

Vero cells (10⁴) were seeded 24 hours before the infection in a 96-well plate (Costar). On the day of infection, the cells were

Table 1. Clinical Characteristics of SARS-CoV-2-Infected Patients Who Received Convalescent Plasma

	Patient				
	1	2	3	4	5
Sex	Male	Male	Female	Female	Male
Age, y	70s	60s	50s	30s	60s
Weight, kg	55	85	60	41.5	87
Smoking	No	No	No	No	No
Blood type	B	B	B	A	B
Coexisting chronic diseases	None	Hypertension; mitral insufficiency	None	None	None
Disease presentation and course					
Estimated incubation period, d ^a	1	7	3	7	15
Interval between symptom onset and admission, d	2	4	2	2	3
Interval between admission and plasma transfusion, d	22	10	20	19	20
Complications prior to plasma transfusion	Bacterial pneumonia; severe ARDS; MODS	Bacterial pneumonia; fungal pneumonia; severe ARDS; myocardial damage	Severe ARDS	Severe ARDS	Severe ARDS
Most severe disease classification	Critical	Critical	Critical	Critical	Critical
Treatments					
Steroids	Methylprednisolone	Methylprednisolone	Methylprednisolone	Methylprednisolone	Methylprednisolone
Antivirals	Lopinavir/ritonavir; interferon alfa-1b; favipiravir	Lopinavir/ritonavir; arbidol; darunavir	Lopinavir/ritonavir; interferon alfa-1b; favipiravir	Interferon alfa-1b; favipiravir	Lopinavir/ritonavir; interferon alfa-1b

Abbreviations: ARDS, acute respiratory distress syndrome; MODS, multiple organ dysfunction syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

^a Estimated incubation period defined as interval between estimated exposure to SARS-CoV-2 and symptom onset.

Table 2. Comparison of Viral Load, Clinical Indexes, and Laboratory Results Before and After Convalescent Plasma Transfusion

Patient	1	2	3	4	5
	1	2	3	4	5
Clinical characteristics					
Body temperature, °C					
Just before transfusion	38.6	39.0	37.6	38.3	39.0
Day 1 posttransfusion	38.5	36.8	37.7	37.9	39.0
Day 3 posttransfusion	38.1	36.6	37.0	36.6	36.8
Day 7 posttransfusion	37.8	37.2	36.5	37.9	36.8
Day 12 posttransfusion	37.0	36.8	36.6	36.8	37.9
SOFA score ^a					
Just before transfusion	5	10	3	3	2
Day 1 posttransfusion	4	12	4	3	2
Day 3 posttransfusion	6	10	3	2	2
Day 5 posttransfusion	5	11	2	2	2
Day 7 posttransfusion	3	7	2	2	1
Day 12 posttransfusion	2	4	2	1	1
PaO ₂ /FiO ₂ ^b					
Just before transfusion	276	209	172	188	205
Day 1 posttransfusion	300	134	184	242	292
Day 3 posttransfusion	220	230	164	233	304
Day 7 posttransfusion	245	206	220	290	230
Day 12 posttransfusion	284	316	342	322	366
Ct value ^c (viral load proxy)					
On admission to hospital	23.0	19.7	18.9	38.0	28.0
Lowest value during hospitalization ^d (highest viral load)	19.2	19.7	18.9	26.6	26.5
Just before plasma transfusion	28.5	22.0	33.0	26.6	35.9
Day 1 posttransfusion	30.0	23.7	38.5	28.0	Negative
Day 3 posttransfusion	34.4	25.0	Negative	Negative	Negative
Day 7 posttransfusion	38.0	32.0	Negative	Negative	Negative
Day 12 posttransfusion	Negative	Negative	Negative	Negative	Negative
Mechanical ventilation					
Onset, days before transfusion	11	2	12	9	2
Extubated, days posttransfusion	Intubated	Intubated	2	9	9
ECMO					
Onset, days before transfusion	Not received	1	Not received	Not received	Not received
Removal, days posttransfusion	NA	5	NA	NA	NA
Laboratory findings					
C-reactive protein, mg/L (normal range, <8)					
Before transfusion	163.4	242.8	65.	156.0	173.1
Day 1 posttransfusion	146.2	223.0	108.3	NT	186.8
Day 3 posttransfusion	115.1	75.2	78.7	160.8	233.7
Day 5 posttransfusion	31.3	10.4	74.7	NT	260.4
Day 7 posttransfusion	31.2	13.9	6.2	9.6	5.5
Day 12 posttransfusion	5.3	33.1	NT	5.8	3.2
Procalcitonin, ng/mL (normal range, <0.1)					
Before transfusion	1.2	7.3	0.1	0.2	0.2
Day 1 posttransfusion	1.3	19.7	0.1	0.08	0.4
Day 3 posttransfusion	1.6	13.9	0.09	0.07	1.5
Day 5 posttransfusion	0.9	1.8	0.08	NT	0.9
Day 7 posttransfusion	1.1	0.1	0.04	0.04	0.09
Day 12 posttransfusion	0.4	0.2	NT	0.04	0.07

(continued)

Table 2. Comparison of Viral Load, Clinical Indexes, and Laboratory Results Before and After Convalescent Plasma Transfusion (continued)

	Patient				
	1	2	3	4	5
IL-6, pg/mL (normal range, 0-7)					
Before transfusion	70.5	438.2	63.9	79.1	87.8
Day 1 posttransfusion	74.9	NT	118.5	39.3	NT
Day 3 posttransfusion	34.5	1045.0	67.0	25.8	797.9
Day 5 posttransfusion	24.1	334.1	590.5	NT	NT
Day 7 posttransfusion	30.8	29.8	174.3	34.0	69.9
Day 12 posttransfusion	6.1	31.8	NT	2.7	54.9
Length of hospital stay, d	Remains hospitalized	Remains hospitalized	53	51	55
Current status as of March 25, 2020	Stable, still receiving mechanical ventilation	Stable, still receiving mechanical ventilation	Discharged home	Discharged home	Discharged home

Abbreviations: Ct, cycle threshold; ECMO, extracorporeal membrane oxygenation; NT, not tested.

^a The SOFA score is calculated using 6 systems: respiratory, coagulation, hepatic, cardiovascular, central nervous system, and kidney. A score of 0 is given for normal function through to 4 for most abnormal for each system. The worst values on each day are recorded, and the final SOFA score is the sum of the scores of each system.

^b $\text{PAO}_2/\text{FiO}_2$ ratio was defined as the ratio of the partial pressure of arterial oxygen to the percentage of inspired oxygen.

^c Cycle threshold is the number of polymerase chain reaction cycles required for gene amplification. A higher Ct value is correlated with a lower viral load.

^d Lowest value (highest viral load) between hospital admission and plasma transfusion.

washed twice. Serum samples from patients were incubated at 56 °C for 30 minutes and then diluted 2-fold in cell culture medium (modified eagle medium). Aliquots (40 μL) of diluted serum samples (from 2-fold to 2056-fold) were added to 50 μL of cell culture medium containing 50 times the tissue culture infective dose (TCID₅₀) of the BetaCoV/Shenzhen/SZTH-003/2020 strain virus (isolated from this hospital, GI-SAID access number: EPI_ISL_406594)¹⁵ on a 96-well plate and incubated at 37 °C for 2 hours in CO₂ 5% vol/vol. Virus antibody mix was then added to cells in 96-well plates and plates were incubated at 37 °C with microscopic examination for cytopathic effect after a 5-day incubation. The highest dilution of serum that showed inhibition activity of SARS-CoV-2 was recorded as the neutralizing antibody titer. Assays were performed in triplicate with negative control samples from healthy volunteers.

Results

Five patients (age range, 36-73 years; 2 women) were treated with convalescent serum. None were smokers, and 4 of 5 had no preexisting medical conditions. All 5 had received various antiviral agents and steroids (Table 1). Convalescent plasma was administered between 10 and 22 days after admission.

The Ct value at the time of admission ranged from 18.9 to 38.0, and on the day of plasma transfusion from 22.0 to 35.9 (Table 2 and Figure 1A). It increased (improved) within 1 day after transfusion. The Ct value of patient 5 became negative on posttransfusion day 1, patient 3 and patient 4 became negative on day 3, and patient 1 and patient 2 became negative on day 12 after the transfusion (Table 2).


The SOFA score ranged from 2 to 10 prior to plasma transfusion, and decreased to a range of 1 to 4 at 12 days following transfusion (Table 2 and Figure 1B). The $\text{PAO}_2/\text{FiO}_2$ ranged from 172 to 276 prior to transfusion, and increased (improved) for 4 of 5 patients within 7 days after transfusion (overall range, 206-290), and increased substantially (range, 284-366) on the 12th day after the plasma treatment (Table 2 and Figure 1C). Body temperature ranged from 37.6 to 39.0 °C before plasma transfusion and declined to the normal range on the third day after the transfusion (Table 2 and Figure 1D).

After the treatment, the values of the inflammatory biomarkers CRP, procalcitonin, and IL-6 of patients 1, 2, 4, and 5 decreased; the values of CRP and procalcitonin of patient 3 decreased (Table 2).

The computed tomography scans of the lungs of these patients all demonstrated severe pneumonia prior to plasma transfusion and showed improvement of the pulmonary lesion of patient 1 on the third day after the plasma transfusion (eFigure 1 in the *Supplement*) and gradual resolution of pulmonary lesions of other patients at 3 days after the plasma treatment (eFigures 2, 3, 4, and 5 in the *Supplement*).

One day prior to convalescent plasma administration, the RBD-specific IgG and IgM ELISA titers of the donors ranged between 1800 and 16 200 (ELISA end point dilution titers) (Table 3). The neutralization titers against SARS-CoV-2 ranged between 80 and 480 (neutralizing end point dilution titers). The RBD-specific IgG ELISA titers of 5 recipients ranged between 1800 and 48 600 and the IgM titers between 5400 and 145 800 a day prior to the convalescent transfusion (eTable in the *Supplement*). After the transfusion of convalescent plasma, the titers of IgG and IgM in the sera of these patients increased in a time-dependent manner. The IgG titers of the

Figure 1. Temporal Changes of Cycle Threshold Value, $\text{PAO}_2/\text{FiO}_2$, SOFA Score, and Body Temperature in Patients Receiving Convalescent Plasma Transfusion



A, Change in cycle threshold (Ct) value in nasopharyngeal swabs of infected patients at day 0, day 3, day 7, and day 12 after the plasma transfusion. A Ct value of 40 was defined as undetectable. B, Change in Sequential Organ Failure Assessment (SOFA) score of the patients with convalescent plasma treatment

(range 0-24, with higher scores indicating more severe illness; see footnote to Table 2 for more complete definition). C, Change in $\text{PAO}_2/\text{FiO}_2$ ratio of the treated patients from day 0 to day 12 after treatment. D, Change in body temperature of the 5 patients following plasma transfusion.

Table 3. Characteristics and Antibody Titer of Convalescent Plasma Donors

	Donors ^a				
	1	2	3	4	5
Blood type	B	B	B	A	B
Donated plasma volume, mL	400	400	400	400	400
Interval between symptom onset and discharge, d	11	11	13	13	11
Interval between discharge and plasma donation, d	11	11	13	11	12
RBD-specific IgG ELISA titer ^b	16 200	1800	1800	5400	16 200
RBD-specific IgM ELISA titer ^c	16 200	1800	5400	5400	5400
Neutralizing antibody titer ^d	240	80	120	240	480

Abbreviation: RBD, receptor binding domain.

^a Donors-patients were matched by number (donor 1 gave plasma to patient 1, etc).

^b ELISA end point dilution titers (IgG antibody). The expected titer of negative control from a healthy person is ≤ 200 .


^c ELISA end point dilution titers (IgM antibody). The expected titer of negative control from a healthy person is ≤ 200 .

^d Neutralization end point dilution titers. The expected titer of negative control from a healthy person is ≤ 10 .

treated patients increased to 145 800, 5400, 5400, 145 800 and 145 800, and the IgM titers increased to 145 800, 5400, 5400, 437 400 and 145 800, respectively, at 3 days after transfu-

sion. These IgG and IgM titers maintained a high level at 7 days after transfusion (Figure 2A and 2B; eTable in the *Supplement*). The neutralizing antibody titers of the 5 recipients

Figure 2. Changes of Receptor Binding Domain-Specific IgG and IgM ELISA and Neutralizing Antibody Titers Before and After Convalescent Plasma Transfusion in Patients



Higher titer values indicate greater protection. A, Variation of RBD-specific IgG ELISA titer. B, Variation of RBD-specific IgM ELISA titer. C, Variation of neutralizing antibody titer against SARS-CoV-2 in recipients in day 0, day 1,

day 3, and day 7 following transfusion. The identical line segments were adjusted slightly to avoid superimposition. RBD indicates receptor binding domain.

ranged between 40 and 160 before transfusion; one day after transfusion, the titers increased to 320, 80, 80, 160, and 240; on day 7, they were 320, 160, 160, 240, and 480, respectively (Figure 2C; eTable in the *Supplement*).

All 5 patients were receiving mechanical ventilation at the time of transfusion, and 3 patients (patients 3, 4, and 5) were weaned from mechanical ventilation (Table 2). Patient 2 was receiving ECMO at the time of plasma treatment but did not require ECMO on day 5 after transfusion (Table 2). Patients 3, 4, and 5 were discharged from the hospital (length of stay: 53, 51, and 55 days, respectively). As of March 25, 2020, patients 1 and 2 remained hospitalized, with lengths of stay of 37 days each.

Discussion

In this case series, 5 patients who were critically ill with COVID-19 were treated with convalescent plasma. As assessed by Ct, viral load declined within days of treatment with convalescent plasma, and the clinical conditions of these patients improved, as indicated by body temperature reduction, improved $\text{PaO}_2/\text{FiO}_2$, and chest imaging. Four patients who had been receiving mechanical ventilation and ECMO no longer required respiratory support by 9 days after plasma transfusion.

Previous studies have reported the use of convalescent plasma transfusion in the treatment of various infections.^{6,10,16} For example, patients ($n = 50$) with SARS had a significantly higher discharge rate by day 22 following onset of illness (73.4% vs 19.0%; $P < .001$) and lower case-fatality rate (0% vs 23.8%; $P = .049$) in the convalescent plasma treatment group ($n = 19$ patients) when compared with steroid treatment group ($n = 21$).¹⁷ In another study of 93 patients with influenza A(H1N1), patients who received convalescent plasma treatment ($n = 20$) compared with those in the control group ($n = 73$)

had significantly fewer deaths (20% vs 54.8%; $P = .01$) and a lower median lymphocyte count on ICU admission.¹⁰

In this study, collection and transfusion of the plasma were done as previously reported.¹⁰ In addition, plasma was obtained from the donors and transfused in the recipients on the same day, which helps preserve the natural activity of the plasma.

Studies have shown that viral loads are highly correlated with disease severity and progression.¹⁸ Fatal outcome of human influenza A(H5N1) has been associated with high viral load and hypercytokinemia.¹⁹ Apart from antiviral treatment, virus-specific neutralizing antibody, which could accelerate virus clearance and prevent entry into target cells, serves as the main mechanism for the restriction and clearance of the viruses by the host.²⁰⁻²² In the current study, SARS-CoV-2 was still detectable in all 5 patients even though antiviral treatment had been given for at least 10 days, although viral load decreased and became undetectable soon after convalescent plasma treatment. As determined by ELISA, all plasma from the donors had high virus-specific IgG and IgM ELISA titers. Moreover, the neutralizing antibody titers, vital for the restriction of viral infection of the 5 recipients, significantly increased after plasma transfusion. The results highlight the possibility that antibodies from convalescent plasma may have contributed to the clearance of the virus and also the improvement of symptoms. In addition to viral neutralizing antibodies, acceleration of infected cell clearance by antibodies has also been found in an in vivo study of HIV-1 virus.²³ In the current study, all patients received antiviral agents, including interferon and lopinavir/ritonavir, during and following convalescent plasma treatment, which also may have contributed to the viral clearance observed.

Limitations

This study has several limitations. First, this was a small case series that included no controls. Second, it is unclear if these patients would have improved without transfusion of

convalescent plasma, although the change in Ct and $\text{PaO}_2/\text{FiO}_2$ represent encouraging findings. Third, all patients were treated with multiple other agents (including antiviral medications), and it is not possible to determine whether the improvement observed could have been related to therapies other than convalescent plasma. Fourth, plasma transfusion was administered 10 to 22 days after admission; whether a different timing of administration would have been associated with different outcomes cannot be determined. Fifth, whether this approach would reduce case-fatality rates is unknown.

ARTICLE INFORMATION

Accepted for Publication: March 20, 2020.

Published Online: March 27, 2020.

doi:10.1001/jama.2020.4783

Author Affiliations: Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China (Shen, Z. Wang, Zhao, Y. Yang, J. Li, Yuan, F. Wang, D. Li, M. Yang, Xing, Wei, Xiao, Y. Yang, Qu, Qing, L. Chen, Xu, Peng, Y. Li, Zheng, F. Chen, Huang, Jiang, D. Liu, Zhang, Y. Liu, L. Liu); Laboratory of Protein Engineering and Vaccines, Tianjin Institute of Industrial Biotechnology, Chinese Academy of Sciences (CAS), Tianjin, China (D. Li, Xiao).

Author Contributions: Dr L. Liu had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Drs Shen, Z. Wang, Zhao, and Y. Yang contributed equally.

Concept and design: Shen, Z. Wang, Yuan, F. Wang, D. Liu, Zhang, Y. Liu, L. Liu.

Acquisition, analysis, or interpretation of data: Shen, Yang Yang, J. Li, Yuan, D. Li, M. Yang, Xing, Wei, Xiao, Yan Yang, Qu, Qing, L. Chen, Xu, Peng, Y. Li, Zheng, F. Chen, Huang, Jiang, Y. Liu, L. Liu.

Drafting of the manuscript: Shen, Zhao, Yang Yang, J. Li, Yuan, F. Wang, M. Yang, Xing, Wei, Xiao, Yan Yang, Qu, Qing, L. Chen, Xu, Zheng, Huang, Jiang, D. Liu, Y. Liu, L. Liu.

Critical revision of the manuscript for important intellectual content: Shen, Z. Wang, Yang Yang, Yuan, D. Li, Peng, Y. Li, F. Chen, Zhang, Y. Liu, L. Liu.

Statistical analysis: Yuan.

Obtained funding: Yuan, Zhang, Y. Liu, L. Liu.

Administrative, technical, or material support: Shen, Zhao, J. Li, Yuan, F. Wang, D. Li, M. Yang, Yan Yang, Qu, Qing, L. Chen, Zhang.

Supervision: Z. Wang, Yuan, Zhang, Y. Liu, L. Liu.

Conflict of Interest Disclosures: None reported.

Funding/Support: This work was supported by the National Science and Technology Major Project (2018ZX10711001, 2017ZX10103011, 2017ZX10204401), Sanming Project of Medicine in Shenzhen (SZSM20141203, SZSM201512005), China Postdoctoral Science Foundation (2019T120147, 2018M641508), Shenzhen Science and Technology Research and Development Project (202002073000001), National Natural Science Foundation of China (81902058), Shenzhen Science and Technology Research and Development Project (202002073000002), and The Key Technology R&D Program of Tianjin (17YFZCSY01090).

Conclusions

In this preliminary uncontrolled case series of 5 critically ill patients with COVID-19 and ARDS, administration of convalescent plasma containing neutralizing antibody was followed by improvement in the patients' clinical status. The limited sample size and study design preclude a definitive statement about the potential effectiveness of this treatment, and these observations require evaluation in clinical trials.

Role of the Funder/Sponsor: The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
2. WHO. Novel coronavirus (COVID-19) situation. Updated March 24, 2020. <https://experience.arcgis.com/experience/685d0ace521648f8a5beeee1b9125cd>
3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *JAMA*. 2020. Published online February 24, 2020. doi:10.1001/jama.2020.2648
4. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends*. 2020;14(1):69-71.
5. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis*. 2020;S1473-3099(20)30141-9.
6. Kraft CS, Hewlett AL, Koepsell S, et al; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit. The use of TKM-100802 and convalescent plasma in 2 patients with Ebola virus disease in the United States. *Clin Infect Dis*. 2015;61(4):496-502.
7. van Grienden J, Edwards T, de Lamballerie X, et al; Ebola-Tx Consortium. Evaluation of convalescent plasma for Ebola virus disease in Guinea. *N Engl J Med*. 2016;374(1):33-42.
8. Florescu DF, Kalil AC, Hewlett AL, et al. Administration of brincidofovir and convalescent plasma in a patient with Ebola virus disease. *Clin Infect Dis*. 2015;61(6):969-973.
9. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. *N Engl J Med*. 2007;357(14):1450-1451.
10. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis*. 2011;52(4):447-456.
11. Burnouf T, Radosevich M. Treatment of severe acute respiratory syndrome with convalescent plasma. *Hong Kong Med J*. 2003;9(4):309.
12. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis*. 2005;24(1):44-46.
13. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. Preprint. *medRxiv*. Preprint posted online February 17, 2020. doi:10.1101/2020.02.11.20021493
14. Villar J, Blanco J, del Campo R, et al; Spanish Initiative for Epidemiology, Stratification & Therapies for ARDS (SIESTA) Network. Assessment of $\text{PaO}_2/\text{FiO}_2$ for stratification of patients with moderate and severe acute respiratory distress syndrome. *BMJ Open*. 2015;5(3):e006812. doi:10.1136/bmjopen-2014-006812
15. Liu C, Yang Y, Gao Y, et al. Viral architecture of SARS-CoV-2 with post-fusion spike revealed by Cryo-EM. *bioRxiv*. Preprint posted online March 5, 2020. doi:10.1101/2020.03.02.972927
16. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J Antimicrob Chemother*. 2005;56(5):919-922.
17. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al; Convalescent Plasma Study Group. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. *J Infect Dis*. 2015;21(1):80-90.
18. Ng KT, Oong XY, Lim SH, et al. Viral load and sequence analysis reveal the symptom severity, diversity, and transmission clusters of rhinovirus infections. *Clin Infect Dis*. 2018;67(2):261-268.
19. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. *Nat Med*. 2006;12(10):1203-1207.
20. Shen C, Chen J, Li R, et al. A multimechanistic antibody targeting the receptor binding site potentially cross-protects against influenza B viruses. *Sci Transl Med*. 2017;9(412):eaam5752.
21. Shen C, Zhang M, Chen Y, et al. An IgM antibody targeting the receptor binding site of influenza B blocks viral infection with great breadth and potency. *Theranostics*. 2019;9(1):210-231.
22. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. *bioRxiv*. Preprint posted online March 12, 2020. doi:10.1101/2020.03.11.987958
23. Lu CL, Murakowski DK, Bournazos S, et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. *Science*. 2016;352(6288):1001-1004.